- Home
- TRP vs EW Comparison
TRP vs EW Comparison
Compare TRP & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRP | EW |
|---|---|---|
| Founded | 1951 | 1958 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.3B | 45.5B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | TRP | EW |
|---|---|---|
| Price | $54.41 | $85.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | $84.00 | ★ $95.83 |
| AVG Volume (30 Days) | 1.8M | ★ 3.6M |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | ★ 4.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.34 | 2.33 |
| Revenue | ★ $10,516,264,743.00 | $5,883,800,000.00 |
| Revenue This Year | $11.86 | $14.26 |
| Revenue Next Year | $6.27 | $9.77 |
| P/E Ratio | ★ $22.35 | $37.47 |
| Revenue Growth | ★ 24.53 | 10.60 |
| 52 Week Low | $43.51 | $65.94 |
| 52 Week High | $55.37 | $87.89 |
Technical Indicators
Market Signals| Indicator | TRP | EW |
|---|---|---|
| Relative Strength Index (RSI) | 54.92 | 56.96 |
| Support Level | $53.29 | $84.64 |
| Resistance Level | $54.95 | $86.19 |
| Average True Range (ATR) | 0.86 | 1.70 |
| MACD | -0.09 | -0.12 |
| Stochastic Oscillator | 64.37 | 65.56 |
Price Performance
Historical ComparisonAbout TRP TC Energy Corporation
TC Energy operates natural gas transmission assets across North America. Segments are determined by country of operation, but both Canadian and US operations are interconnected. Mexican operations are disconnected from the US and only have one customer, the state utility CFE. They also operate power generation assets, with the largest being the Bruce Power nuclear plant.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.